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Favorable Prognostic Factors for Survival in Non-small Cell
Lung Cancer
A Comprehensive Analysis of 26,957 Patients with NSCLC
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Shimao Fukai, MD,† Atsuhisa Tamura, MD,‡ Ryusei Saito, MD,§ Yosihito Maruyama, PhD,
Masaaki Kawahara, MD,* and Sai-Hong Ignatius Ou, MD, PhD¶
Background: Performance status (PS) is an important factor in
determining survival outcome in non-small cell lung cancer
(NSCLC) but is generally confounded by stage, age, gender, and
smoking status. We investigated the prognostic significance of PS
taking into account these important factors.
Methods: Retrospective analysis of registry database of the National
Hospital Study Group for Lung Cancer (NHSGLC) between1990
and 2005. Univariate analysis was performed using Kaplan-Meier
method. Multivariate analysis was performed using Cox propor-
tional hazards model to identify independent prognostic factors.
Results: A total of 26,957 patients with NSCLC were analyzed of
which 12,613 patients (46.8%) had World Health Organization
(WHO) PS  0, 8,137 patients were never smokers (30.2%), and
most of them were females (72.7%). The majority of PS  0
patients presented with stage I disease (56.9%). Patients with
PS  0 constituted the group with the highest proportion of never
smokers (36.7%). There was a significant difference in the median
overall survival (OS) between patients with PS  0 and PS  1 (51.5
months versus 15.4 months, respectively; p  0.0001) and among
patients with various PS within individual American Joint Commit-
tee on Cancer stage (all p values 0.0001). Never smokers had
significantly improved median OS than ever smokers (30.0
months versus 19.0 months, respectively; p  0.0001). Multivar-
iate analysis demonstrated good PS, never smoker (versus ever
smoker; hazard ratio  0.935, 95% confidence interval: 0.884–
0.990; p  0.0205), early stage, female gender, squamous cell
carcinoma histology, and treatment were all as independent
favorable prognostic factors.
Conclusions: PS and smoking status are independent prognostic
factors for OS in NSCLC.
Key Words: WHO performance status, Smoking status, Gender,
Prognostic factors, Non-small cell lung cancer, Histology, Cancer
registry, National Hospital Study Group for Lung Cancer
(NHSGLC).
(J Thorac Oncol. 2010;5: 620–630)
The International Association for the Study of LungCancer (IASLC) International Staging Committee
(ISC) has proposed revisions to the tumor, node, metasta-
sis (TNM) descriptors and stage groupings for lung can-
cer.1–4 These revisions were based on retrospective sur-
vival analysis of a very large database compiled by IASLC
and validated by showing better discrimination of survival
by the revisions to TNM descriptors and stage group-
ings.5,6 In addition, ISC also analyzed additional patient-
related and tumor-related prognostic factors for survival
using the same retrospective ISC database. Using recursive
partitioning and amalgamation, ISC has shown that besides
clinical stage, performance status (PS) was found to be a
significant independent prognostic factor in NSCLC, and
good PS patients were found in early-stage non-small cell
lung cancer (NSCLC).7,8 Because data on smoking status
were limited, it was not taken into consideration in the
reports.7,8 Increased tobacco exposure has been shown to
be related to increased comorbidities and decreased PS,
especially after a diagnosis of lung cancer.9 It has been
well established that smoking status is another independent
prognostic factor for survival in NSCLC.10,11 Furthermore,
never smokers are more likely to be females with adeno-
carcinoma.12 Indeed, despite numerous publications on
prognostic factors in NSCLC, few studies had large
enough patients to analyze the distribution and prognostic
significance of PS among all stages of NSCLC while
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TABLE 1. Clinicopathologic Characteristics of Patients with NSCLC According to WHO Performance Status
WHO Performance Status (PS)
P0 1 2 3 4
N (%)a 12,613 (46.9) 9243 (34.4) 2879 (10.7) 1453 (5.4) 712 (2.6)
Median age (yr) (95% CI) 67 (47–80) 69 (48–82) 71 (49–85) 73 (53–86) 71 (50–87) 0.0001
Median follow-up time (mo)
(range)
13.6 (0–134) 9.0 (0–129) 4.6 (0–119) 2.7 (0–49) 1.6 (0–76) 0.0001
Smoking status
Never smoker 4625 (36.7) 2060 (22.3) 713 (24.8) 405 (27.9) 234 (32.9)
Ever smoker 7868 (62.4) 7086 (76.7) 2127 (73.9) 1029 (70.8) 465 (64.0)
Unknown 122 (1.0) 97 (1.0) 39 (1.4) 19 (1.3) 22 (3.1) 0.0001
Gender
Male 8346 (66.2) 7093 (76.7) 2209 (76.7) 1079 (74.3) 511 (71.8)
Female 4244 (33.6) 2140 (23.2) 669 (23.2) 372 (25.6) 201 (28.2)
Unknown 23 (0.2) 10 (0.1) 1 (0.1) 2 (0.1) 0 (0.0) 0.0001
Age category
0–39 158 (1.3) 111 (1.2) 26 (0.9) 7 (0.5) 5 (0.7)
40–49 735 (5.8) 455 (4.9) 120 (4.2) 35 (2.4) 23 (3.2)
50–59 2198 (17.4) 1368 (14.8) 328 (11.4) 122 (8.4) 76 (10.7)
60–69 4431 (35.1) 2959 (32.0) 831 (28.9) 398 (27.4) 201 (28.2)
70–79 4235 (33.6) 3339 (36.1) 1094 (38.0) 569 (39.2) 259 (36.4)
80 781 (6.2) 978 (10.6) 472 (16.4) 318 (21.9) 147 (20.6)
Unknown 75 (0.6) 33 (0.4) 8 (0.3) 4 (0.3) 1 (0.1) 0.0001
AJCC stage
I 7179 (56.9) 1800 (19.5) 247 (8.5) 86 (5.8) 21 (2.9)
II 959 (7.6) 597 (6.5) 127 (4.4) 40 (2.8) 15 (2.1)
III 3119 (24.7) 4015 (43.4) 1193 (41.4) 525 (36.1) 207 (29.1)
IV 1251 (9.9) 2716 (29.4) 1277 (44.4) 767 (52.8) 451 (63.3)
Unknown 105 (0.8) 115 (1.2) 35 (1.2) 35 (2.4) 18 (2.5) 0.0001
Histology
Adenocarcinoma 8118 (64.4) 4518 (48.9) 1458 (50.6) 765 (52.6) 386 (54.2)
Squamous cell carcinoma 3572 (28.3) 3838 (41.5) 1133 (39.4) 548 (37.7) 249 (35.0)
Large cell carcinoma 435 (3.4) 551 (6.0) 186 (6.5) 94 (6.5) 40 (5.6)
Other 244 (1.9) 147 (1.6) 34 (1.2) 7 (0.5) 5 (0.7)
Unknown 244 (1.9) 189 (2.0) 68 (2.4) 39 (2.7) 32 (4.5) 0.0001
Period of diagnosis
1990–1996 5839 (46.3) 4802 (52.0) 1611 (56.0) 759 (52.2) 380 (53.3)
1997–2001 4204 (33.3) 2837 (30.7) 800 (27.8) 448 (30.8) 203 (28.5)
2002–2005 3001 (23.8) 1581 (17.1) 459 (15.9) 242 (16.7) 126 (17.7)
Unknown 19 (0.2) 23 (0.2) 9 (0.3) 4 (0.3) 3 (0.4) 0.0001
Surgery
Yes 9932 (78.7) 3004 (32.5) 278 (9.7) 47 (3.2) 10 (1.4)
No 2632 (20.9) 6166 (66.7) 2582 (89.7) 1395 (96.0) 695 (97.6)
Unknown 49 (0.4) 73 (0.8) 19 (0.7) 11 (0.8) 7 (1.0) 0.0001
Radiation
Yes 1992 (15.8) 3487 (37.7) 1143 (39.7) 496 (34.1) 205 (28.8)
No 10,499 (83.2) 5690 (61.6) 1722 (59.8) 949 (65.3) 506 (71.1)
Unknown 122 (1.0) 66 (0.7) 14 (0.5) 8 (0.6) 1 (0.1) 0.0001
Chemotherapy
Yes 4423 (35.1) 4834 (52.3) 1355 (47.1) 519 (35.7) 155 (21.8)
No 8115 (64.3) 4383 (47.4) 1511 (52.5) 926 (63.7) 555 (77.9)
Unknown 75 (0.6) 26 (0.3) 13 (0.5) 8 (0.6) 2 (0.3) 0.0001
a Percentage calculated across the row.
WHO, World Health Organization; NSCLC, non-small cell lung cancer; AJCC, American Joint Committee on Cancer.
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taking into account potential confounding factors such as
age, gender, smoking status, and stage.13 In this report, we
used the patient database of the National Hospital Study
Group for Lung Cancer (NHSGLC) in Japan and per-
formed a comprehensive analysis of the clinicopathologic
characteristics of patients with NSCLC according to World
TABLE 2. Clinicopathologic Characteristics of Patients with NSCLC According to Smoking Status and Stratified by Gender
Ever Smoker (N  18,820) Never Smoker (N  8137)
Male Female P Male Female P
N (%)a 17,060 (90.6) 1760 (9.4) 2221 (27.3) 5916 (72.7)
Median age (yr) (95% CI) 69 (49–82) 69 (45–83) 0.6065 70 (47–84) 67 (47–83) 0.0001
Median follow-up time (mo) (range) 8.9 (0–134) 9.5 (0–125) 0.0792 9.3 (0–119) 11.9 (0–127) 0.0001
Age category
0–39 140 (0.8) 37 (2.1) 46 (2.1) 82 (1.4)
40–49 772 (4.5) 127 (7.2) 104 (4.7) 371 (6.3)
50–59 2456 (14.4) 279 (15.9) 309 (13.9) 1078 (18.2)
60–69 5840 (934.2) 479 (27.2) 643 (929.0) 1889 (31.90
70–79 6212 (926.4) 630 (35.8) 789 (35.5) 1886 (31.9)
80 1585 (99.3) 202 (11.5) 319 (14.4) 589 (10.0)
Unknown 55 (0.3) 6 (0.3) 0.0001 11 (0.5) 21 (0.4) 0.0001
WHO performance status (PS)
0 7181 (42.1) 670 (38.1) 1071 (48.2) 3546 (59.9)
1 6390 (37.5) 688 (39.1) 625 (28.1) 1433 (24.2)
2 1918 (11.2) 209 (11.9) 255 (11.5) 457 (7.7)
3 921 (95.4) 106 (6.0) 141 (6.4) 264 (4.5)
4 398 (2.3) 58 (3.3) 95 (4.3) 139 (2.4)
Unknown 252 (1.5) 29 (1.7) 0.0044 34 (1.5) 77 (1.3) 0.0001
AJCC stage
I 4983 (29.2) 588 (33.4) 838 (37.7) 2953 (49.9)
II 1258 (7.4) 115 (6.5) 117 (5.3) 249 (4.2)
III 6556 (38.4) 612 (34.8) 698 (31.40 1205 (20.4)
IV 4061 (23.8) 426 (24.2) 536 (24.1) 1449 (24.5)
Unknown 202 (1.2) 19 (1.1) 0.0008 32 (1.4) 60 (1.0) 0.0001
Histology
Adenocarcinoma 7583 (44.5) 969 (55.1) 1471 (66.2) 5263 (89.0)
Squamous cell carcinoma 7764 (45.5) 632 (35.9) 593 (26.7) 359 (6.1)
Large cell carcinoma 1029 (6.0) 90 (5.1) 71 (3.2) 122 (2.1)
Other 304 (1.8) 29 (1.7) 28 (1.3) 75 (1.3)
Unknown 380 (2.2) 40 (2.3) 0.0001 58 (2.6) 97 (1.6) 0.0001
Period of diagnosis
1990–1996 8446 (49.5) 843 (47.9) 1041 (46.9) 2704 (45.7)
1997–2001 5218 (30.6) 575 (32.7) 756 (34.0) 1950 (33.0)
2002–2005 3359 (19.7) 339 (19.3) 418 (18.8) 1251 (21.2)
Unknown 37 (0.2) 3 (0.2) 0.1982 6 (0.30 11 (0.2) 0.0707
Surgery
Yes 9079 (53.2) 966 (54.9) 1103 (49.7) 2338 (39.5)
No 7875 (46.2) 783 (44.5) 1106 (49.8) 3544 (59.9)
Unknown 106 (0.6) 11 (0.6) 0.1795 12 (0.5) 34 (0.6) 0.0001
Radiation
Yes 11,563 (67.8) 1257 (71.4) 1679 (75.6) 4905 (82.9)
No 5371 (31.5) 492 (28.0) 529 (23.8) 950 (16.1)
Unknown 126 (0.7) 11 (0.6) 0.0021 13 (0.6) 61 (1.0) 0.0001
Chemotherapy
Yes 9522 (55.8) 1071 (60.9) 1374 (61.9) 3582 (60.6)
No 7460 (43.7) 682 (38.8) 839 (37.8) 2305 (39.0)
Unknown 78 (0.5) 7 (0.4) 0.0001 8 (0.4) 29 (0.5) 0.3068
a Percentage calculated across the row.
NSCLC, non-small cell lung cancer; WHO, World Health Organization; AJCC, American Joint Committee on Cancer.
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Health Organization (WHO) PS and smoking status and ana-
lyzed the relationship between PS and stage, age, and smoking
status. Furthermore, we performed univariate and multivari-
ate survival analyses to determine the prognostic significance
of PS while taking into account stage, age, gender, and
smoking status.
PATIENTS AND METHODS
Database
The NHSGLC was established in 1972 and funded by
the Japanese government at the same time that a lung
cancer registry was also established. Information on more
than 2000 patients with lung cancer was collected each
year and represent 3 to 4% of all Japanese patients with
lung cancer. The NHSGLC consists of 42 National Hos-
pital Organizations nationwide in Japan. Information in the
registry includes the institution, the time of patient diag-
noses, age, gender, WHO PS, smoking status, tumor his-
tology, TNM classification, treatment type (surgery, radio-
therapy, and chemotherapy), response to initial first-line
chemotherapy in advanced patients, cause of death, and
survival time. Stage of disease is from pathologic stage if
available otherwise from clinical stage. Data for each
patient is sent to the central registry office after every
discharge from the hospital.14,15
In this study, smoking status was categorized as ever
smoker or never smoker. A never smoker was coded as a
patient who smoked fewer than 100 cigarettes during his or
her lifetime. A patient who smoked more than 100 ciga-
rettes or was defined as an ever smoker. The study period
was divided into 3 periods according to the year of ap-
proval for docetaxel (1997) and gefitinib (2002) in Japan.
The last follow-up date was January 20, 2007, and at that
time, 43.3% of the patients have died.
Statistical Analyses
Comparisons of demographic, clinical, and patho-
logic variables were made for patients with NSCLC, using
Pearson 2 statistic for nominal variables. Comparison of
nonparametric values across two groups were done using
Wilcoxon rank sum test. Univariate survival rate analyses
were estimated using the Kaplan and Meier method, with
comparisons made between groups by the log-rank test.
Cox proportional hazards modeling using time since diag-
nosis were performed. All statistical analyses were con-
ducted using SAS 8.2 statistical software (SAS Institute,
Inc., Cary, NC). Statistical significance was assumed for a
two-tailed p value less than 0.05.
RESULTS
Patient Characteristics by PS
A total of 26,957 patients with NSCLC were ana-
lyzed and 46.9% of them presented with PS  0. PS  0
patients had the youngest median age at time of diagnosis.
TABLE 3. Distribution of PS According to AJCC Stage and
Smoking Status
PS
AJCC Stage (All Patients)
I
(N  9333)
II
(N  1738)
III
(N  9059)
IV
(N  6462)
0 7179 (76.9) 959 (55.2) 3119 (34.4) 1251 (19.4)
1 1800 (19.3) 597 (34.3) 4015 (44.3) 2716 (42.0)
2 247 (2.6) 127 (7.3) 1193 (13.2) 1277 (19.8)
3 86 (0.9) 40 (2.3) 525 (4.8) 767 (11.9)
4 21 (0.2) 15 (0.9) 207 (2.3) 451 (7.0)
AJCC Stage (Never Smoker)
I
(N  3750)
II
(N  362)
III
(N  1883)
IV
(N  1957)
0 3185 (84.9) 221 (61.0) 755 (40.1) 433 (22.1)
1 468 (12.5) 96 (26.5) 689 (36.6) 776 (39.7)
2 62 (1.7) 30 (8.3) 241 (12.8) 372 (19.0)
3 23 (0.6) 9 (2.5) 136 (7.2) 228 (11.7)
4 12 (0.3) 6 (1.7) 62 (3.3) 148 (7.6)
AJCC Stage (Ever Smoker)
I
(N  4952)
II
(N  1361)
III
(N  7083)
IV
(N  4421)
0 3390 (68.5) 728 (53.5) 2336 (33.0) 804 (18.2)
1 1309 (26.4) 499 (36.7) 3293 (46.5) 1905 (43.1)
2 184 (3.7) 94 (6.9) 932 (13.2) 891 (20.2)
3 61 (1.2) 31 (2.3) 386 (5.4) 527 (11.9)
4 8 (0.2) 9 (0.7) 136 (1.9) 294 (6.7)
Percentages are given in parentheses.
AJCC, American Joint Commission on Cancer.
TABLE 4. Distribution of PS According to Age Category
PS
Age Category (yr)
0–39
(N  307)
40–49
(N  1368)
50–59
(N  4092)
60–69
(N  8820)
70–79
(N  9496)
80
(N  2696)
0 158 (51.5) 735 (53.7) 2198 (53.7) 4431 (50.2) 4235 (44.6) 781 (29.0)
1 111 (36.2) 455 (33.3) 1368 (33.4) 2959 (33.5) 3339 (35.2) 978 (36.3)
2 26 (8.5) 120 (8.8) 328 (8.0) 831 (9.4) 1094 (11.5) 472 (17.5)
3 7 (2.3) 35 (2.6) 122 (3.0) 398 (4.5) 569 (6.0) 318 (11.8)
4 5 (1.6) 23 (1.7) 76 (1.9) 201 (2.3) 259 (2.7) 147 (5.5)
Percentages are given in parentheses.
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The median follow-up time was the longest among PS  0
patients, which reflected the much improved survival of
PS  0 patients. Additionally, the majority of PS  0
patients presented with stage I disease (56.9%), and there
was a significant decrease in the proportion of stage I
disease among patients with PS 0. The majority of the
PS  4 patients (63.3%) presented with stage IV disease.
The proportion of female patients was also the highest
among PS  0 patients. Similarly, the proportion of never
smokers was highest among PS  0 patients. The complete
clinicopathologic characteristics of patients with NSCLC
according to PS are listed in Table 1.
FIGURE 1. A, Kaplan-Meier survival curves of patients with non-small cell lung cancer (NSCLC) according to World
Health Organization (WHO) performance status (PS). B, Kaplan-Meier survival curves of patients with NSCLC according
to smoking status.
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Patient Characteristics by Gender and Smoking
Status
Eight thousand one hundred forty-eight patients (30.2%)
were never smokers. Median age of never smokers was 68 years,
when compared with 69 years in ever smokers, and the differ-
ence was statistically significant (p  0.0001). Never smokers
presented with a higher proportion of stage I disease than ever
smokers regardless of gender. There was an increase in the
proportion of females (72.7%) among never smokers, when
compared with ever smokers (9.4%). Among never smokers,
female patients were younger, had better PS, and presented with
more earlier stage and more adenocarcinoma histology. On the
other hand, male patients presented with higher proportion of
squamous cell carcinoma regardless of smoking status. Clinico-
pathologic characteristics of the patients stratified by smoking
status and gender are listed in Table 2.
Distribution of PS among Individual Stage by
Smoking Status
The distribution of patients with various PS among indi-
vidual American Joint Committee on Cancer (AJCC) stage
overall and by smoking status is listed in Table 3. The majority
of AJCC stage I and II patients had PS  0 regardless of
smoking status. The proportion of patients with PS  0 was
consistently higher among never smokers than ever smokers
among all stages. The proportion of patients with poor PS (PS
3 and PS  4) was 18.9% among stage IV patients, when
compared with 1.1% among stage I patients.
Distribution of PS among Age Categories
The distribution of patients with various PS among the
different age categories is listed in Table 4. More than half of the
patients with NSCLC among 0 to 39, 40 to 49, 50 to 59, 60 to
69 years age categories presented with PS  0. Patients with
PS  0 was again the most common proportion of the patients
within age category 70 to 79, but they made up less than 50% of
the patients. Patients with PS  1 was the most common
proportion (36.3%) of patients within age category of 80. Simi-
larly, the proportion of patients with poor (PS  3 and PS  4)
steadily increased in proportion with increasing age from 3.9%
among 0 to 39 patients to 17.3% among 80 patients.
Univariate Overall Survival Analysis
Performance Status
The 1-year, 5-year survival estimate, and median overall
survival (OS) for PS 0 patients were 84.9%, 45.9%, and 51.5
months, respectively. The corresponding values for PS  1
patients were 57.8%, 18.7%, and 15.4 months, respectively,
32.3%, 5.8%, and 6.7 months, respectively, for PS 2 patients,
20.6%, 0.0%, and 3.9 months, respectively, for PS 3 patients,
and 10.3%, 0.0%, and 2.4 months, respectively, for PS  4
patients. The difference in OS was statistically significant (p 
0.0001) (Figure 1A).
Smoking Status
The 1-year, 5-year survival estimate, and median OS
for never smokers were 72.8%, 34.9%, and 29.9 months,
respectively, which were statistically improved over the cor-
responding values for ever smokers (61.8%, 26.3%, and 19.0
months; p  0.0001) (Figure 1B).
Gender (Overall and by Smoking Status)
The 1-year, 5-year survival estimate, and median OS
for female patients were 73.3%, 35.3%, and 30.5 months,
respectively, which was statistically improved over the cor-
responding values for male patients (61.8%, 26.2%, and 19.0
months, respectively; p  0.0001). Among never smokers,
the 1-year, 5-year survival estimate, and median OS for
female patients were 75.7%, 36.7%, and 33.9 months, respec-
tively, which was statistically improved over the correspond-
ing values for male patients (64.8%, 29.9%, and 22.1 months,
respectively; p  0.0001). Among ever smokers, the 1-year,
5-year survival estimate, and median OS for female patients
were 65.3%, 30.6%, and 22.0 months, respectively, which was
statistically improved over the corresponding values for male pa-
tients (61.4%, 25.8%, and 18.8 months, respectively; p 0.0001).
PS by AJCC Stage
We then analyzed survival of patients by PS within
individual stage. The 1-year, 5-year survival estimate, and
median OS are listed in Table 5 with corresponding Kaplan-
Meier survival curves plotted as Figures 2A–D. Worsening
PS is associated with poorer survival.
PS by Smoking Status
We then analyzed survival of patients by PS according
to smoking status. The 1-year, 5-year survival estimate, and
median OS are listed in Table 6. Worsening PS is associated
with poorer survival.
TABLE 5. 1-Year, 5-Year Survival Estimate, and Median OS
of Patients by PS within Individual Stage
PS
1 yr
(%)
5 yr
(%)
Median OS
(mo) P
AJCC stage I 0 (N  7197) 96.1 63.3 91.6
1 (N  1800) 90.7 48.4 55.3
2 (N  247) 82.0 25.7 26.3
3 (N  86) 81.3 0.0 30.9
4 (N  21) 41.9 0.0 10.0 0.0001
AJCC stage II 0 (N  959) 87.7 37.7 39.1
1 (N  597) 77.0 28.2 29.7
2 (N  127) 66.7 16.4 19.1
3 (N  40) 45.6 0.0 12.1
4 (N  15) 47.0 0.0 7.3 0.0001
AJCC stage III 0 (N  3119) 74.5 27.1 24.6
1 (N  4015) 55.5 14.7 14.2
2 (N  1193) 36.9 6.8 8.2
3 (N  525) 26.3 0.0 5.6
4 (N  207) 10.7 0.0 3.1 0.0001
AJCC stage IV 0 (N  1251) 48.3 18.1 11.7
1 (N  2716) 35.0 9.3 8.3
2 (N  1277) 15.8 8.7 4.4
3 (N  767) 9.8 0.0 2.8
4 (N  451) 8.0 1.6 2.1 0.0001
OS, overall survival; AJCC, American Joint Committee on Cancer.
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Multivariate Analysis
The following variables were analyzed by Cox propor-
tional hazards method: AJCC stage, age (as a continuous
variable), gender, smoking status, histology, WHO PS, sur-
gery, radiation, and chemotherapy, and the results are shown
in Table 7. Good PS, female gender, never smoker, early
stage, squamous cell carcinoma histology, and treatment
received (surgery, radiation, and radiation) were found to be
FIGURE 2. A, Kaplan-Meier survival curves of patients with stage I non-small cell lung cancer (NSCLC) according to World
Health Organization (WHO) performance status (PS). B, Kaplan-Meier survival curves of patients with stage II NSCLC accord-
ing to WHO PS. C, Kaplan-Meier survival curves of patients with stage III NSCLC according to WHO PS. D, Kaplan-Meier sur-
vival curves of patients with stage IV NSCLC according to WHO PS.
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significantly and independently associated with improved
survival. In addition, multivariate survival analysis was also
performed focusing on PS within surgical and nonsurgical
subgroups (Table 8). In the patients who did not undergo
surgery, again PS was a clearly significant prognostic factor,
whereas in those who underwent surgery, the trend was
almost similar except for the PS  4 patients. On the other
hand, large cell carcinoma was an unfavorable independent
prognostic factor. Gender, smoking history, stage, and histol-
ogy were subsequently excluded individually and in combi-
nation from the full Cox model to determine how they
affected covariate PS in the model. The largest changes in the
FIGURE 2. (Continued).
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estimates were1%, thus the final Cox models included each
covariate. Goodness of fit for the Cox models was assessed
with use of the 2 statistic.
DISCUSSION
Although PS is generally accepted as an important
factor in determining survival outcome in NSCLC, there is
limited literature on the distribution of PS among patients
with NSCLC, its relationship to stage, age, smoking status,
and gender, and the prognostic significance of PS in the
context of these characteristics. This is likely due to the fact
that national cancer registries such as Surveillance, Epidemi-
ology, and End Results in the United States do not routine
abstract data on PS or smoking status. Additionally, clinical
trials generally limit enrollment to patients with PS 0 to 2.
Many factors conspire to result in poor PS in patients with
NSCLC including large tumor burden, advanced age, and
comorbidities such as chronic obstructive pulmonary disease,
peripheral vascular disease, and coronary artery disease from
heavy tobacco exposure. To complicate the analysis of PS
further, it is now generally accepted that NSCLC in never
smokers is a distinct clinical entity predominance of younger,
female patients with adenocarcinoma, distinct genetic alter-
ations from smokers, and better survival outcome.12 Thus,
gender, stage, and histology in addition to stage are important
variables that need to be taken into account when performing
analysis of PS in NSCLC.
In this report, we performed the largest study (26,957
patients) and a comprehensive analysis of the distribution of
PS among all stages of NSCLC, its relationship to age,
gender, and smoking status, and determine the prognostic
significance of PS after accounting for these potential con-
founding factors.
Patients with PS 0 were generally younger, presented
with predominantly stage I disease, and had the highest
proportion of never smokers, females, and adenocarcinoma
histology among all PS patients. On the other hand, patients
with PS  4 had the lowest proportion of patients receiving
chemotherapy despite having the highest proportion of stage
IV disease. In agreement with Sculier et al., we observed a
strong relationship between PS and stage as evidenced by the
proportion of patients with PS  0 progressively decreased
with advanced stage regardless of smoking status. We also
observed a strong relationship between PS and age. The
proportion of the very elderly (80) patients increased from
6.2% among PS  0 patients to 20.6% among PS  4
patients (Table 1). Similarly, the proportion of patients with
PS  0 decreased with advanced age especially among age
categories 70 to 79 and 80 patients, whereas the proportion
of poor PS patients (PS  3 and PS  4) increased with
advancing age (Table 3). Altundag et al.16 observed similar
significant relationship between PS and very elderly patients
but not with weight loss and the very elderly patients.
TABLE 6. 1-Year, 5-Year Survival Estimate, and Median OS
of Patients by PS According to Smoking Status
PS
1 yr
(%)
5 yr
(%)
Median OS
(mo) P
Never smoker 0 (N  4625) 89.8 51.4 63.3
1 (N  2060) 62.1 16.8 16.7
2 (N  713) 35.0 8.5 7.3
3 (N  405) 22.0 0.0 4.3
4 (N  234) 12.3 0.0 2.9 0.0001
Ever smoker 0 (N  7868) 82.1 42.7 46.0
1 (N  7086) 56.6 19.2 15.0
2 (N  2127) 31.3 4.9 6.5
3 (N  1029) 20.2 0.0 3.8
4 (N  465) 9.3 0.0 2.1 0.0001
OS, overall survival.
TABLE 7. Cox Model for Overall Survival for All Patients
Hazard
Ratio
95% Confidence
Interval P
Age 1.002 1.000–1.004 0.0221
Gender
Male 1.000
Female 0.797 0.753–0.843 0.0001
Smoking status
Smoker 1.000
Never smoker 0.935 0.884–0.990 0.0205
WHO performance status
0 1.000
1 1.293 1.229–1.359 0.0001
2 2.044 1.914–2.183 0.0001
3 2.944 2.714–3.193 0.0001
4 4.179 3.756–4.650 0.0001
AJCC stage
I 1.000
II 1.933 1.750–2.136 0.0001
III 2.812 2.631–3.005 0.0001
IV 4.652 4.321–5.010 0.0001
Histology
Adenocarcinoma 1.000
Squamous cell
carcinoma
0.900 0.860–0.942 0.0001
Large cell carcinoma 1.226 1.129–1.330 0.0001
NOS/mixed/other 1.485 1.277–1.728 0.0001
Period of diagnosis
2002–2005 1.000
1997–2001 1.661 1.535–1.796 0.0001
1990–1996 1.570 1.456–1.694 0.0001
Surgerya
No 1.000
Yes 0.383 0.360–0.407 0.0001
Radiationa
No 1.000
Yes 0.896 0.858–0.936 0.0001
Chemotherapy
No 1.000
Yes 0.802 0.768–0.838 0.0001
a Unknown included but not shown.
AJCC, American Joint Committee on Cancer; WHO, World Health Organization;
NOS, not otherwise specified.
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Similar relationship between PS and smoking status
was observed because the proportion of patients with PS  0
was consistently higher among never smokers than ever
smokers regardless of gender (Table 2) or stage (Table 3).
There was a progressive decline in median OS with declining
PS with the most dramatic decline from PS  0 to PS  1
patients with a decrease of 36 months in median OS. Fur-
thermore, within stage I and II patients, there were dramatic
decreases in median OS from PS  0 to PS  4 patients of
81.6 months and 31.8 months, respectively. We also demon-
strated that never smokers contained a high proportion of
female patients and adenocarcinoma. Never smokers had
significantly improved survival outcome, when compared
with ever smokers by univariate analysis. Female patients
also had significantly improved survival outcome than male
patients regardless of smoking status. By multivariate analy-
sis, PS, stage, smoking status, gender, and age are all inde-
pendent prognostic factors. Albain et al.17 analyzed 2531
patients with advanced stage NSCLC and found that PS, age,
and gender are all independent prognostic factors, but smok-
ing status was not available. Radzikowska et al.18 analyzed
20,561 patients with NSCLC of all stages with smoking
status and arrived at the same conclusion. Only 4.3% of the
patients were never smokers, and patient survival was not
further analyzed by smoking status or was smoking status
factored into the Cox multivariate analysis. Finally, we dem-
onstrated that squamous cell carcinoma is an independent
favorable prognostic factor similar to what has been reported
by IASLC ISC,7,8 whereas large cell carcinoma is an unfa-
vorable prognostic factor.
A significant proportion of the patients with NSCLC in
this study had PS 0 to 1 likely due to the fact that most of the
participating physicians in the NHSGLC are surgeons and
more patients with early stage NSCLC are treated. Lilenbaum
et al.19 reported a high proportion of PS 2 to 4 among patients
with NSCLC, but 20% of the patients were hospitalized, and
50% of patients were receiving chemotherapy at the time of
study. One limitation of this study is that the PS was recorded
by healthcare providers. There are reports that healthcare
providers tend to underestimate PS, when compared with
patients’ self-assessment.19,20 However, retrospective analy-
sis of a doublet chemotherapy regimen versus single-agent
chemotherapy trial indicated PS  2 patients derived OS
benefit from doublet chemotherapy.21 A randomized phase II
trial in PS2 patients demonstrated that doublet chemotherapy
conferred a median survival of 9.7 months, when compared
with 6.5 months with erlotinib alone with no difference in
quality of life.22 These observations were further confirmed in
a recent published phase III trial that enrolled exclusively 400
PS2 patients where first line platinum-doublet chemotherapy
regimens achieved a median survival of about 7.9 months.23
In all these trials, the PS were assessed by healthcare provid-
ers. Although these patients were likely to have really poor
PS, healthcare provider assessment of PS is still valid for
clinical purposes.
Finally, there are three major scales used by physicians
to measure PS in oncology: Karnofsky PS, Eastern Cooper-
ative Oncology Group (ECOG PS), and WHO PS. Karnofsky
PS ranges from 0 to 100, in 10-point increments to define 11
different PS levels from dead (0) to fully normal functioning
(100). ECOG PS has six levels ranging from 0 (fully ambu-
latory without symptoms) to 5 (dead). WHO PS is very
similar to ECOG PS except there is no level 5 (dead).
Buccheri et al.24 have shown that ECOG PS is better than
Karnofsky PS in discriminating patients with different prog-
nosis. Thus, WHO PS is a valid measure of PS in NSCLC and
has been used in pivotal trials such as the Iressa Pan-Asia
Study.25 In summary, in this report, we performed the largest
analysis to date of the distribution of PS using the WHO scale
among all stages of disease in terms of its relationship to age,
gender, smoking status, and stage. We demonstrated interre-
lationship among PS and stage, age, and smoking status.
Multivariate analysis demonstrated WHO PS, stage, smoking
status, gender, and age were all independent prognostic fac-
tors for OS in NSCLC.
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